1. N1H- and N1-Substituted Phenylguanidines as α7 Nicotinic Acetylcholine (nACh) Receptor Antagonists: Structure–Activity Relationship Studies
- Author
-
Osama I. Alwassil, Marvin K. Schulte, Sanjay S Aripaka, Malgorzata Dukat, Jens D. Mikkelsen, and Shailesh Khatri
- Subjects
0303 health sciences ,Physiology ,medicine.drug_class ,Stereochemistry ,Cognitive Neuroscience ,Substituent ,Antagonist ,Cell Biology ,General Medicine ,Receptor antagonist ,Biochemistry ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Nicotinic agonist ,chemistry ,medicine ,Structure–activity relationship ,Guanidine ,030217 neurology & neurosurgery ,Acetylcholine ,030304 developmental biology ,Acetylcholine receptor ,medicine.drug - Abstract
We previously reported that N-(3-chlorophenyl)guanidine (1) represents a novel α7 nicotinic ACh (nACh) receptor antagonist chemotype. In the present study, a small series of compounds was synthesized with the intent to investigate the structure-activity relationship (SAR). Preliminary data suggested that the N-methyl analog of 1, 2, was several times more potent. Therefore, the chloro group at the aryl 3-position of 1 and its N1-methyl counterpart 2 were replaced with a number of substituents considering the electronic, lipophilic, and steric nature of the substituents. The potencies of the compounds to inhibit acetylcholine (ACh)-induced responses were obtained in Xenopus laevis oocytes expressing human α7 nicotinic ACh receptors (nAChRs) using a two-electrode voltage-clamp assay. We found that the nature of the 3-position substituents had relatively little (i.e.
- Published
- 2021
- Full Text
- View/download PDF